daclatasvir   Click here for help

GtoPdb Ligand ID: 11266

Synonyms: BMS-790052 | BMS790052 | Daklinza®
Approved drug
daclatasvir is an approved drug (EMA (2014), FDA (2015))
Compound class: Synthetic organic
Comment: Daclatasvir is an orally available anti-hepatitis C virus (HCV) drug, It is a direct-acting inhibitor of the non-structural protein 5A (NS5A) replication complex of HCV [1]. Blocking NS5A function inhibits viral RNA replication and virion assembly.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 12
Hydrogen bond donors 4
Rotatable bonds 17
Topological polar surface area 174.64
Molecular weight 738.39
XLogP 5.11
No. Lipinski's rules broken 3
Click here for help
Canonical SMILES COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc([nH]1)c1ccc(cc1)c1ccc(cc1)c1cnc([nH]1)[C@@H]1CCCN1C(=O)[C@H](C(C)C)NC(=O)OC)C(C)C
Isomeric SMILES COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc([nH]1)c1ccc(cc1)c1ccc(cc1)c1cnc([nH]1)[C@@H]1CCCN1C(=O)[C@H](C(C)C)NC(=O)OC)C(C)C
InChI InChI=1S/C40H50N8O6/c1-23(2)33(45-39(51)53-5)37(49)47-19-7-9-31(47)35-41-21-29(43-35)27-15-11-25(12-16-27)26-13-17-28(18-14-26)30-22-42-36(44-30)32-10-8-20-48(32)38(50)34(24(3)4)46-40(52)54-6/h11-18,21-24,31-34H,7-10,19-20H2,1-6H3,(H,41,43)(H,42,44)(H,45,51)(H,46,52)/t31-,32-,33-,34-/m0/s1
No information available.
Summary of Clinical Use Click here for help
Daclatasvir is used to treat hepatitis C infection. It is often used in fixed-dose combination with sofosbuvir. EMA and FDA authorisations have been withdrawn or discontinued, but the drug is available in other jurisdictions and is still on the WHO essential medicines list of anti-HCV drugs.
External links Click here for help